RE: So13 Apr 2021 12:53
I haven't said they failed, I said it could fail. We just don't know. All i know is it's April 2021 and their is no approved product, no saliva, no BAMS, no LFT. LfT is the closest and all we have is 30 Spanish people saying it worked. I dont care what the reasons are because I used up those excuses in Q4. It's now Q2. Simple facts, to date they have failed to bring to market a working test after 12 months of the project. Dont care who is to blame, that is the simple FACT. I know all this can change just with one RNS which is why im holding on.
Regarding the company and my investment is linked, yes of course they are tied, but there are differences. As a shareholder I am disappointed with their communication to investors, failure to meet deadlines, failure to update when the deadlines have been missed. Another difference will be the numbers. The company could be happy to put affimers on the map but not make too much money from it, which will hit the valuation we are putting on the company (which is already a concern for some). A business focused on shareholder return would have already launched V1 of the test, generating shareholder value and derisking the V2. They have not. A good company doesnt always mean its a good investment (although I do believe/hope Avacta is one)